Managing the post-myocardial infarction patient with asymptomatic left ventricular dysfunction

Cardiology

Volumn 105, Issue 2, 2006, Pages 95-107

  Philippides, George J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blockers; Angiotensin converting enzyme inhibitors; Asymptomatic left ventricular dysfunction; Carvedilol; Post myocardial infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VALSARTAN;

ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MASS SCREENING; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUDDEN DEATH;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 31944452310     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089970     Document Type: Review

References (52)

1. American Heart Association: Heart Disease and Stroke Statistics - 2005 Update. Dallas, American Heart Association, 2005.
2. Kannel WB, Sorlie P, McNamara PM: Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979;44:53-59.
3. Zijlstra F, Hoorntje JC, de Boer MJ, et al: Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413-1419.
4. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-1574.
5. Gheorghiade M, Bonow RO: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998;97:282-289.
6. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
7. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-691.
8. Wang TJ, Evans JC, Benjamin EJ, et al: Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977-982.
9. Kober L, Torp-Pedersen C, Carlsen JE, et al: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
10. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
11. Schwarz ER, Schaper J, vom Dahl J, et al: Myocyte degeneration and cell death in hibernating human myocardium. J Am Coll Cardiol 1996;27:1577-1585.
12. Elsasser A, Schlepper M, Klovekorn WP, et al: Hibernating myocardium: an incomplete adaptation to ischemia. Circulation 1997;96:2920-2931.
13. Olivetti G, Capasso JM, Sonnenblick EH, Anversa P: Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 1990;67:23-34.
14. Erlebacher JA, Weiss JL, Weisfeldt ML, Bulkley BH: Early dilation of the infarcted segment in acute transmural myocardial infarction: role of infarct expansion in acute left ventricular enlargement. J Am Coll Cardiol 1984;4:201-208.
15. Gaudron P, Eilles C, Ertl G, Kochsiek K: Compensatory and noncompensatory left ventricular dilatation after myocardial infarction: time course and hemodynamic consequences at rest and during exercise. Am Heart J 1992;123:377-385.
16. Rodriguez JA, Godoy I, Castro P, et al: Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study. Rev Med Chil 1997;125:643-652.
17. Moller JE, Dahlstrom U, Gotzsche O, et al: Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. Am Heart J 2004;147:494-501.
18. McDonald KM, Chu C, Francis GS, et al: Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction. J Mol Cell Cardiol 1997;29:3203-3210.
19. Wijns W, Vatner SF, Camici PG: Hibernating myocardium. N Engl J Med 1998;339:173-181.
20. Wilson JR, Martin JL, Schwartz D, Ferraro N: Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation 1984;69:1079-1087.
21. LeJemtel TH, Maskin CS, Lucido D, Chadwick BJ: Failure to augment maximal limb blood flow in response to one-leg versus two-leg exercise in patients with severe heart failure. Circulation 1986;74:245-251.
22. GISSI-3 Investigators: GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1994;343:1115-1122.
23. ISIS-4 Collaborative Group: ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-685.
24. Crilley JG, Farrer M: Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart 2001;86:638-642.
25. Bettencourt P, Ferreira A, Pardal-Oliveira N, et al: Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol 2000;23:921-927.
26. Choy AM, Darbar D, Lang CC, et al: Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994;72:16-22.
27. Darbar D, Gillespie N, Choy AM, et al: Diagnosing left ventricular dysfunction after myocardial infarction: the Dundee algorithm. QJM 1997;90:677-683.
28. GISSI Investigators: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;i:397-402.
29. Serruys PW, Simoons ML, Suryapranata H, et al: Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986;7:729-742.
30. Grines CL, Cox DA, Stone GW, et al: Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949-1956.
31. CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390.
32. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005;112:1825-1852.
33. St John SM, Pfeffer MA, Plappert T, et al: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.
34. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
35. McMurray J, Kober L, Robertson M, et al: Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005;45:525-530.
36. GlaxoSmithKline: Coreg Prescription Information. Philadelphia, GlaxoSmithKline, 2003.
37. Doughty RN, Whalley GA, Walsh HA, et al: Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109:201-206.
38. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-1066.
39. Vantrimpont P, Rouleau JL, Wun CC, et al: Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997;29:229-236.
40. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ: Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33:916-923.
41. Pitt B, Remme W, Zannad F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
42. Dahlof B, Lindholm LH, Hansson L, et al: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285.
43. Kostis JB, Davis BR, Cutler J, et al: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212-216.
44. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ: Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001;38:421-428.
45. Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
46. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-254.
47. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
48. Julian DG, Camm AJ, Frangin G, et al: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-674.
49. Buxton AE, Lee KL, Fisher JD, et al: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-1890.
50. Moss AJ, Zareba W, Hall WJ, et al: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883.
51. Gruberg L: DINAMIT: the Defibrillator in Acute Myocardial Infarction Trial. Medscape/ACC Annual Scientific Session, 2004. Available at www.medscape.com/viewarticle/472003; Accessed November 23, 2005.
52. St John Sutton M, Pfeffer MA, Plappert T, et al: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.